Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Disease area: Airway diseases

Abstract

Effects of tiotropium, an inhaled long acting anti-cholinergic agent, on lung function were investigated in current smokers and non-smokers with asthma treated with inhaled glucocorticoids (ICS) plus long acting b₂-agonists.We conducted a double-blind, placebo-controlled, cross-over study of inhaled single dose of tiotropium in 10 asthmatics current smoking and 10 asthmatics who have never smoked. Lung function was measured before and 1, 3 and 24 hours after inhalation of 18 mg of tiotropium or placebo by HandiHaler®. The primary outcome was a change in forced expiratory volume in 1 second (FEV₁) from baseline, and the secondary outcomes were changes in peak expiratory flow rate (PEFR), V₅₀ and V₂₅.At baseline, asthmatics with and without smoking history had a mean FEV₁ that was 2,590ml and 2,220ml, and were taking a mean dose of ICS of 1,208 and 1,000 mg/day, respectively. The increase from baseline FEV₁ was 169ml and 105ml higher at 3 hours after tiotropium than after placebo in current smokers and non-smokers, respectively.



PEFR, V₅₀ and V₂₅ were also significantly increased after tiotropium compared with placebo in both study groups. Changes in FEV₁ and PEFR tended to be greater in asthmatics current smoking compared with subjects who have never smoked, although there were no statistical differences at any time points.These findings suggest that tiotropium will provide a new strategy on treatment of bronchial asthma.


Rating:

Share or cite this content

Citations should be made in the following way:
Makoto Yoshida (Fukuoka, Japan), Makoto Yoshida, Tomoaki Iwanaga, Hiromasa Inoue. Effects of tiotropium on lung function in current smokers and never smokers with asthma. Eur Respir J 2015; 46: Suppl. 59, 2950

Member's Comments

No comment yet.

Related content which might interest you: Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Small airway function in smokers without airway obstruction Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 Effect of dual bronchodilation with indacaterol/glycopirronium on small airways resistance in patients with stable COPD Source: International Congress 2016 – Non-inflammatory COPD monitoring Year: 2016 Effects of inhaled furosemide on exercise capacity and on dyspnea in patients with COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effect of smoking on lung function in adult-onset asthma Source: International Congress 2015 – Molecular pathways of lung injury due to tobacco-related products Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effect of breathing parameters on lung dose in case of two combination drugs used in asthma and COPD therapy Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Lung function change and exacerbations in patients with COPD in the WISDOM study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Induced sputum cytology and pulmonary function tests in ex-smoker asthmatic patients controlled with inhaled steroid and long acting beta agonist therapy Source: International Congress 2015 – Monitoring airway diseases with lung function tests Year: 2015 The effects of bronchodilators on regional lung sound distribution in patients with COPD Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013 The effect of smoking cessation on methacholine responsiveness in young asthma patients Source: Annual Congress 2013 –Monitoring lung function in airway diseases Year: 2013 Body-plethysmographic measurements of bronchodilator response in stable COPD Source: International Congress 2014 – Airways: reversibility and responsiveness Year: 2014 Bronchodilator response of advanced lung function parameters depending on COPD severity Source: International Congress 2016 – Functional assessment of the airways Year: 2016 B2-adrenoceptor genotype16 influences airway calibre but not hyperresponsiveness in asthmatics using regular B2-agonist in addition to inhaled corticosteroids Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 The effect of Vitamin D deficiency on lung function in current smoker COPD patients Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The effect of tiotropium bromide on lung function parameters in patients with asthma- COPD overlap syndrome Source: International Congress 2016 – Asthma points to ponder Year: 2016